Introduction {#sec1-1}
============

Tinnitus is the perception of sound in the absence of an external acoustic stimulus. Prolonged tinnitus frequently has a marked negative impact on the quality of life, causing a great deal of psychological distress.^[@ref1]^ Owing to the increasing use of personal headsets, especially among young adults,^[@ref2]^ tinnitus presents a serious health issue. The exact mechanism underlying tinnitus is unclear. Animal models have contributed to understanding the mechanism underlying tinnitus, and salicylate-induced tinnitus in rats serves as a popular animal model for the study of tinnitus.^[@ref3]^ Earlier studies showed long-term administration of salicylate can increase the distortion product of acoustic emissions,^[@ref6]^ increase outer hair cell electromotility,^[@ref5],[@ref7]^ modify the average spectrum of electrophysiological cochleoneural activity^[@ref8],[@ref9]^ and induce tinnitus reliably.

Several pieces of evidence indicate spontaneous neuronal activity in auditory regions might be involved in the physiological processes underlying salicylate-induced tinnitus. An increase to various degrees in the spontaneous activity of auditory neurons after administration of salicylate has been reported at the level of the auditory nerve,^[@ref8],[@ref9]^ the inferior colliculus (IC)^[@ref10],[@ref11]^ and the auditory cortex (AC).^[@ref12],[@ref13]^ Salicylate can have a direct influence on the spontaneous activity of different types of neurons in the central auditory system in an *in vitro* brain slice.^[@ref14],[@ref15]^ Immediate-early gene (IEG) activation is considered part of a general neuronal response to natural stimuli and a result of normal synaptic activity. The immunohistochemistry of IEG expression is a useful method to visualize activated neuronal populations in the brain of animals.^[@ref16]^ IEG expression reflects recent neuronal activity. Some IEGs, especially *Arc* or *Egr-1*, appear to be highly correlated with sensory evoked neuronal activities,^[@ref17]^ and they are induced rapidly in neurons by patterned synaptic activity that activates *N*-methyl-D-aspartate (NMDA) receptors.^[@ref18]^ However, there are few reports of their relationship with tinnitus induced by longtime administration of salicylate.

In this study, the gap prepulse inhibition of acoustic startle (GPIAS) paradigm was used to detect salicylate-induced tinnitus-like behavior in rats.^[@ref19]^ We investigated the expression levels of *Arc, Egr-1* and *NMDA receptor subunit 2B (NR2B)* genes in the IC and AC in response to acute and chronic administration of salicy-late. Interestingly, *Arc* and *Egr-1* expression was reduced significantly in the IC and AC. Reduction of both *Arc* and *Egr-1* expression might be involved with instability of homeostatic plasticity in tinnitus.

Materials and Methods {#sec1-2}
=====================

Animals {#sec2-1}
-------

Experimental procedures were approved by the Animal Care and Use Committee of the Shanghai Jiao Tong University School of Medicine. A total of 48 adult male Sprague Dawley^®^ rats (body weight 250-350g) were divided into four groups on the basis of our earlier study:^[@ref6],[@ref7]^ i) control group (n=9); ii) acute treatment group with salicylate injected once (n=6); iii) chronic treatment groups with daily injections of salicylate for 3 days (n=6) (S3), 7 days (n=6) (S7) or 14 days (n=9) (S14); iv) recovery groups with 14 days (n=6) (S14+R14) and 28 days (n=6) (S14+R28) post-chronic salicylate administration.

Design and salicylate administration {#sec2-2}
------------------------------------

Sodium salicylate (Sigma-Aldrich, Shanghai, China) was dissolved in normal saline (9% (w/v) NaCl) at a final concentration of 200 mg/mL. Rats in the acute treatment group received a single intraperitoneal injection of salicylate (400 mg/kg). Rats were anesthetized deeply with sodium pentobarbital (40 mg/kg, administered intraperitoneally) and sacrificed 2 h later. Rats in the chronic treatment groups were given an intraperitoneal injections of salicylate (200 mg/kg) daily at 08:00 h and at 16:00 h for 3 (S3), 7 (S7) or 14 (S14) consecutive days and were sacrificed at 08:00 h on days 4 (S3), 8 (S7) or 15 (S14), respectively. The recovery groups were given intraperitoneal injections for 14 consecutive days and recovery of 14 days (S14+R14) and 28 days (S14+R28), respectively, after cessation of treatment. The control group was given intraperitoneal injections of saline (200 mg/kg) twice daily at 8:00 and 16:00 for 14 consecutive days.

Gap detection testing {#sec2-3}
---------------------

Tinnitus was assessed using the GPIAS paradigm as described in detail elsewhere.^[@ref19],[@ref20]^ This program exploits the acoustic startle reflex in animals treated with salicylate. GPIAS testing began 1 h before rats were sacrificed. Each animal was placed in a permeable sound box resting on a sensitive piezoelectric transducer capable of generating a voltage proportional to the magnitude of the startle response evoked by sound stimuli generated digitally by a digital signal processor (RZ6, Tucker Davis Technologies, Alachua, FL, USA). The amplitude of the startle response was collected by a computer and analyzed offline.

GPIAS sessions consisted of 30 gap trials and 30 no-gap trials. Rats underwent testing with different band-pass-filtered (1000-Hz bandwidth) sounds centered at 6, 12 and 16 kHz at a sound level of 65 dB SPL. Startle responses were elicited by a 20-ms burst of white noise at 100 dB SPL. The gap in the narrowband noise began 100 ms before the onset of the broadband startling noise and the last 50 ms. The interval between each startling noise was 30-35 s^[@ref20]^ and each test lasted 30 min.

Percentage GPIAS was calculated by computing the average ratio of trials with a gap versus no-gap trials for each frequency using the formula:

\[(AvgTnogap -- AvgTgap) / AvgTnogap\]×100%

where AvgTgap was the average amplitude during gap trials and AvgTnogap was the average amplitude of no-gap trials.^[@ref21],[@ref22]^

Quantitative real-time PCR {#sec2-4}
--------------------------

Rats were sacrificed after deep anesthesia was induced by an injection of pentobarbital (40 mg/kg body weight). IC and AC were dissected rapidly and total RNA was extracted from each sample with TRIzol reagent according to the manufacturer's protocol. Extracted RNA was quantified spectrophotometrically at 260 and 280 nm. High-quality RNA was reverse transcribed into complementary DNA (cDNA) using a Reverse Transcription Kit (DRR036A, TaKaRa). Primers for Arc, Egr-1, NR2B and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), designed by Takara (Otsu, Japan), were obtained from Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. The PCR primer sequences were:

1.  Arc-F, 5'-CTGCCACAGAAGCAGGGTGA-3'

2.  Arc-R, 5'-AGGGTGCCCACCACATACTGA-3'

3.  Egr-1-F, 5'-GAACAACCCTACGAGCACCTG-3'

4.  Egr-1-R, 5'-GCCACAAAGTGTTGCCACTG-3'

5.  NR2B-F, 5'-TGGCTATCCTGCAGCTGTTTG-3'

6.  NR2B-R,5'-TGGCTGCTCATCACCTCATTC-3'

7.  GAPDH-F, 5'-GGCACAGTCAAGGCTGAGAATG-3'

8.  GAPDH-R,5'-ATGGTGGTGAAGACGCCAGTA-3'

PCR amplification was done with SYBR^®^ Premix Ex Taq™ (DRR420A, TaKaRa). The PCR protocol was: 95°C for 30 s, followed by 40 cycles of 95°C for 5 s, 60°C for 34 s and a final dissociation stage, using the ABI 7500 realtime PCR system (Applied Biosystems, Foster City, CA, USA). We assumed the amplification efficiency of the target and reference were approximately equal. Relative quantification and calculations were done with the comparative threshold (*C*~t~) cycle method (2^--ΔΔ*C*t^).^[@ref23]^

Western blot {#sec2-5}
------------

Total proteins were extracted from the samples and their concentration was determined using an ultraviolet spectrophotometer (DR/4000UV-VIS, Hach Co., Loveland, CO, USA). SDS-PAGE (12% (w/v) polyacrylamide gel) was used to electrophorese Arc and Egr-1 protein and SDS-PAGE (8% (w/v) polyacry-lamide gel) was used to electrophorese NR2B protein: equal quantities of protein were loaded. After separation, proteins were transferred electrophoretically to polyvinylidene difluoride membranes, which were blocked in Tris-buffered saline, 0.1% (v/v) Tween20, 5% (w/v) skimmed milk powder and then incubated with primary antibodies overnight and washed in Tris-buffered saline, 0.1% Tween20. Secondary antibodies were diluted in blocking buffer and incubated with the membranes for 2 h at room temperature. Finally, the immunoreactive bands were visualized by the SuperSignal Chemilumnescent Substrate system (Pierce). The images of western blot analysis were quantified by Image Lab software, and band intensities of Arc, Egr-1 and NR2B were expressed relative to GAPDH. The following antibodies were used: 1:1000 rabbit polyclonal anti-Arc antibody (ab23382, Abcam, Shanghai, China), 1:1000 rabbit anti-Egr-1 antibody (4153S, Cell Signaling Technology, Danvers, MA, USA), 1:1000 rabbit anti-NMDAR2Bantibody (4212S, Cell Signaling Technology) and 1:5000 goat anti-rabbit IgG-HRP (Jackson).

Immunohistochemistry {#sec2-6}
--------------------

Rats were anesthetized deeply and perfused through the ascending aorta with normal saline followed by 4% (v/v) paraformaldehyde. The brain was removed and IC and AC were dissected. Immunostaining was done on paraffin-embedded sections of rat IC and AC, which were then deparaffinized in xylene and rehydrated rapidly through a graded series of alcohol. Excess liquid was removed and the sections were washed in phosphate-buffered saline (PBS), pH 7.4, 0.05% (v/v) Tween20 (PBS-T). In order to reduce nonspecific binding, normal goat serum (1% (v/v) in PBS) was applied to slides for 30 min at 37 °C. The sections were then incubated with primary antibody on consecutive sections. Sections were rinsed with PBS-T then incubated with secondary antibodies for 1 h at room temperature. The immunoreactions were visualized using 0.015% (v/v) H~2~O~2~ in 3,3'-diaminobenzidinete-trahydrochloride (DAB)/Tris-buffered saline for 10 min at room temperature. The following antibodies were used: 1:50 rabbit anti-Arc antibody (ab23382, Abcam), 1:50 rabbit anti-Egr-1 antibody (4153S, Cell Signaling Technology) and 1:50 rabbit anti-NMDAR2B antibody (4212S, Cell Signaling Technology).

Immunostaining was assessed quantitatively with the Microimage Analysis Program (Optimas 6.5, Media Cybernetics, Rockville, MD, USA). In brief, sections were placed under a microscope (Olympus BX 50) and the image was transferred to a computer via a digital camera (Nikon CoolPix 950). In each section, areas of positive immunostaining of neurons in the bilateral hemispheres were selected and the integrated optical density (OD) was measured in three sections from IC and AC in each rat for *Arc*, *Egr-1* and *NR2B*. The results were expressed as the percentage of relative OD units compared to the control groups, which were given a value of 100%. The OD values obtained in three sections per rat were averaged and used to calculate the group means. Photomicrographs for coronal sections of the IC and AC were taken and analyzed using image J software to evaluate the number of immunoreactive neurons (IRN). The density of IRN was expressed as mean ± standard deviation (SD) of the number of positive neurons/section, and the significance of any difference in density of IRN between control and S14 groups for structures on the same side were determined using a two-tailed *t*-test.

Statistical analysis {#sec2-7}
--------------------

All data were calculated and presented as mean ± standard deviation. According to the distribution of the data and the homogeneity of variance, unpaired, two-sided Student's *t*-test and one-way analysis of variance (ANOVA) followed by Student-Newman-Keuls (SNK) *post-hoc* tests were used for comparisons among groups. The level of statistically significant difference was set at P≤0.05.

Results {#sec1-3}
=======

Salicylate-induced tinnitus-like behavior in rats {#sec2-8}
-------------------------------------------------

Chronic treatment groups (S3, S7 and S14) showed a statistically significant decrease in GPIAS values relative to the control group at 12 kHz and 16 kHz but not at 6 kHz, indicating these animals were experiencing tinnitus. However, there was no difference in GPIAS values in any other group, indicating tinnitus-like behavior disappeared 14 days after treatment with salicylate ceased ([Figure 1](#fig001){ref-type="fig"}).

Expression of *Arc, Egr-1* and *NR2B* in the inferior colliculus {#sec2-9}
----------------------------------------------------------------

Compared to the control group, *Arc* mRNA expression was down-regulated significantly in the IC in the acute treatment and chronic treatment groups (S3, S7 and S14) and expression of the Arc protein was decreased significantly in the IC in the chronic treatment groups (S3, S7 and S14), but there was no significant change in any other group ([Figure 2](#fig002){ref-type="fig"}). The immunoreactivity of Arc in the IC of the chronically treated group (S14) was significantly lower compared to the control group ([Figure 3 A](#fig003){ref-type="fig"},[B](#fig003){ref-type="fig"},[C](#fig003){ref-type="fig"}). Egr-1 mRNA expression was decreased significantly in the IC in the acute and chronic treatment groups (S3, S7 and S14) compared to the control group. Expression of the Egr-1 protein was decreased significantly in the IC in the chronic treatment groups (S7 and S14). There was no significant change in any other group ([Figure 2](#fig002){ref-type="fig"}). The immunoreactivity of Egr-1 of the salicylate-treated group (S14) was significantly lower in the IC compared to the control group ([Figure 3A](#fig003){ref-type="fig"},[B](#fig003){ref-type="fig"},[C](#fig003){ref-type="fig"}). NR2B mRNA and protein expression were up-regulated significantly in the IC in rats that were chronically administered salicylate (S3, S7 and S14) compared to the control group. There was no significant change in the acute treatment group or recovery groups after treatment with salicylate ceased ([Figure 2](#fig002){ref-type="fig"}). The immunoreactivity of NR2B in the IC of the chronic treatment group (S14) was significantly higher compared to the control group ([Figure 3 A](#fig003){ref-type="fig"},[B](#fig003){ref-type="fig"},[C](#fig003){ref-type="fig"}).

Expression of *Arc, Egr-1* and *NR2B* in the auditory cortex {#sec2-10}
------------------------------------------------------------

Compared to the control group, *Arc* mRNA and protein expression were down-regulated significantly in the AC chronically administered salicylate (S3, S7 and S14). There was no significant change in the acute treatment or recovery groups after treatment with salicylate ceased ([Figure 4](#fig004){ref-type="fig"}). The immunoreactivity of Arc in the AC of the chronic treatment group (S14) was significantly lower compared to the control group ([Figure 5A](#fig005){ref-type="fig"},[B](#fig005){ref-type="fig"},[C](#fig005){ref-type="fig"}). Expression of Egr-1 mRNA was decreased significantly in the AC in the chronic treatment groups (S3, S7 and S14) and expression of the Egr-1 protein was decreased significantly in the AC in the chronic treatment groups (S7 and S14) compared to the control group. There was no significant change in the acute treatment group or recovery groups after treatment with salicylate ceased ([Figure 4](#fig004){ref-type="fig"}). The immunoreactivity of Egr-1 of the salicylate-treated group (S14) was significantly lower in the AC compared to the control group ([Figure 5A](#fig005){ref-type="fig"},[B](#fig005){ref-type="fig"},[C](#fig005){ref-type="fig"}). The relative mRNA and protein expression levels of NR2B under different salicylate treatment regimens. The levels of mRNA and protein expression of NR2B were up-regulated significantly in the AC in rat groups chronically administered salicylate (S3, S7 and S14) compared to the control group. Moreover, the increase was not found in the acute treatment group nor was it observed in the recovery groups (S14+R14, S14+R28) after treatment with salicylate ceased ([Figure 4](#fig004){ref-type="fig"}). The immunoreactivity of NR2B in the AC of the chronic treatment group (S14) was significantly higher compared to the control group ([Figure 5A](#fig005){ref-type="fig"},[B](#fig005){ref-type="fig"},[C](#fig005){ref-type="fig"}).

Discussion {#sec1-4}
==========

The expression of IEGs (*Arc* and *Egr-1*) is clearly attuned to altered neural activity and synaptic efficacy in neurons as well as related plasticity changes, and they have been validated as an indirect marker of neuronal activity in the hippocampus,^[@ref24]^ amygdala^[@ref25]^ and sensory cortices.^[@ref26]^ Hyperactivity in the auditory center is considered to be associated with tinnitus, and earlier reports believed that salicylate-induced tinnitus was associated with up-expression of Egr-1 and NR2B genes in the cochlear.^[@ref5],[@ref30]^ We hypothesize, therefore, an increase of Arc and Egr-1 will be observed in auditory center in the tinnitus model. In this study, however, we found expression of both *Arc* and *Egr*-1 genes was decreased significantly in the IC and AC in rats with tinnitus, whereas expression of *NR2B* was increased following long-term administration of salicylate. All of these changes had returned to normal 14 days after treatment with salicylate ceased.

Earlier studies showed^[@ref5],[@ref30]^ the NMDA receptor has the major role in inducing Arc or Egr-1 expression.^[@ref18],[@ref31]^ and some NMDA receptor antagonists, such as Gacyclidine,^[@ref34]^ might be potent drugs for the suppression of sensorineural tinnitus in humans and, therefore, should be considered for long-term human use and warrant clinical trials. However, expression of Arc or Egr-1 was inconsistent with increased expression of NR2B in our study. NMDA receptor activation is not the sole mechanism with which to induce Arc mRNA transcription and Arc transcription is under the control of both NMDA and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.^[@ref35]^ The cytoskeletal protein Arc is increased following long-term potentiation (LTP)-like activity of sustained scale AMPA receptors in postsynaptic membranes of dendritic spines,^[@ref36]^ which increases sensitivity to glutamate and synaptic strength.^[@ref37]^ Moreover, Arc-mediated synaptic scaling is essential for neurons in response to continuous activity changes, maintaining averaged firing rate^[@ref38]^ and homeostatic adaptation.

Sometimes, unrestrained neuronal input can result in saturation of the neuronal ability to encode information.^[@ref39]^ Homeostatic compensation for these alterations in synaptic strength is required to maintain neuronal output in the normal range. For example, chronic blockade of network activity for several days resulted in an increase in surface and synaptic AMPA receptors, whereas a chronic increase in activity reduces the number of surface and synaptic AMPA receptors.^[@ref40]^ Arc is essential for mediating the homeostatic scaling of AMPA receptors. Over-expression of Arc blocks the up-regulation of surface AMPA receptors and miniature excitatory postsynaptic currents (mEPSCs) induced by chronic neuronal inactivity. Conversely, Arc knockout (KO) neurons exhibit a scaled increase in surface AMPA receptors and AMPA receptor-mediated mEPSCs, which mimics the up-regulation of synaptic function induced by chronic inactivity. Arc protein is regulated dynamically by chronic changes in neuronal activity that normally evokes synaptic scaling^[@ref36]^ and is highly sensitive to plasticity, specifically homeostatic scaling.^[@ref41]^ Decreased Arc expression would result in abnormal synaptic scaling and instability of long-lasting forms of synaptic efficacy and synaptic plasticity in rats with tinnitus, which appeared to have maladaptive neuroplastic brain alterations. Arc expression returned to normal after 14 days accompanied by the disappearance of tinnitus and restoration of normal synaptic plasticity.

Reduction of Arc, as shown here for animals with tinnitus, results in loss of the normal scaling responses to changes of neuronal activity.^[@ref36]^ Hippocampal neurons derived from Arc/Arg3.1 KOs displayed larger basic mEPSCs and failed to undergo synaptic scaling adequately.^[@ref36]^ Moreover, the highly synchronized epilepticlike cortical network activity could be observed in the cortex following Arc decline.^[@ref42]^ The abnormally high degree of synchronization and epileptic-like neuronal activity in AC are assumed to be associated with tinnitus.^[@ref43]^ By application of different models of tinnitus, the decline of *Arc* mRNA was observed following a strong acoustic trauma induced with a sound of 120 dB SPL for 2 h.^[@ref41],[@ref44]^ The failure to mobilize Arc in the cortex could suggest that tinnitus is linked to a failure to adapt central circuits to reduced cochlear input.

Egr-1 is expressed in the neocortex, primary olfactory cortex, entorhinal cortex, hippocampus, amygdaloid nuclei, nucleus accumbens, striatum and cerebellar cortex of rat brain.^[@ref45]^ Egr-1 shows some characteristics similar to those of Arc; they share some of the binding sites on the promoter region, and both are activated by the mitogen-activated protein (MAP) kinase pathway.^[@ref46],[@ref47]^ Moreover, Egr-1 is a molecular marker of sensory input^[@ref48]^ and has a crucial role in maintenance of late-phase LTP.^[@ref49]^

Egr-1 deletion has been shown to lead to impaired *in vivo* late-phase LTP and deficits in long-term memory formation.^[@ref50]^ Egr-1 expression is down-regulated markedly in visual deprivation,^[@ref48]^ *post-mortem* brains of patients with schizophrenia^[@ref51]^ and exposure to social isolation stress.^[@ref52]^ Similar to Arc expression, the *Egr-1* genes expression decreased in the IC and AC in rats with tinnitus following long-term administration of salicylate and returned to normality 14 days later, accompanied by disappearance of tinnitus. We hypothesize instability of long-lasting forms of homeostatic plasticity in tinnitus causes the decline of Egr-1 expression and this speculation requires further experimental support.

In conclusion, tinnitus induced with long-term salicylate administration was correlated with decreased expression of Arc and Egr-1 and increased expression of NR2B in the IC and AC. All returned to normal 14 days after treatment with salicylate ceased. These results showed long-term administration of salicylate induced tinnitus markedly but reversibly and caused neural changes of plasticity at the IC and AC level. Decreased expression of Arc and Egr-1 might serve as a marker of instability of long-lasting forms of synaptic plasticity.

![Effects of salicylate on gap prepulse inhibition of acoustic startle (GPIAS) values. Chronic treatment groups (S3, S7 and S14) showed a significant decrease in GPIAS values compared to the control group at 12 kHz and 16 kHz but not at 6 kHz. There was no difference of GPIAS values among the acute treatment recovery (S14+R14, S14+R28) and control groups.](ejh-2014-1-2294-g001){#fig001}

![Expression of Arc, Egr-1 and NR2B in the IC. The expression of Arc and Egr-1 mRNA was significantly lower in the acute treatment group and chronic treatment groups (S3, S7and S14) compared to the control and recovery groups (S14+R14, S14+R28). The protein expression of Arc and Egr-1 were significantly lower in the chronic treatment groups (S7 and S14) compared to any other group. However, the expression levels of NR2B (A) mRNA and (B) protein were significantly higher in chronic treatment groups (S3, S7 and S14) compared to any other group. \*P\<0.05 *vs* the control group; \*\*P\<0.01 *vs* the control group.](ejh-2014-1-2294-g002){#fig002}

![The expression of Arc, Egr-1 and NR2B was evaluated using immunohisto-chemistry staining (magnification 400×) in the IC. A) Immunohistochemical staining of Arc, Egr-1 and NR2B in the IC. Black arrows indicate neurons and white arrows indicate glia. B) The number of Arc, Egr-1and NR2B positively stained cells in IC. C) Bars show percentage difference in OD compared to the control group (100%). Values are given as mean ± SD, n=6.\*P\<0.05 *vs* the control group. Scale bars: 30 μm.](ejh-2014-1-2294-g003){#fig003}

![Expression of Arc, Egr-1 and NR2B in the AC. The expression levels of Arc and Egr-1were significantly lower in rats chronically administered with salicylate (S3, S7 and S14) compared to the control, acute treatment and recovery groups (S14+R14, S14+R28), indicated by real-time PCR and western blot assays. However, the expression levels of NR2B (A) mRNA and (B) protein were significantly higher in chronic treatment groups (S3, S7 and S14) compared to any other group. \*P\<0.05 *vs* the control group; \*\*P\<0.01 *vs* the control group.](ejh-2014-1-2294-g004){#fig004}

![The expression of Arc, Egr-1 and NR2B was evaluated using immunohisto-chemistry staining (magnification 400×) in the AC. A) Immunohistochemical staining of Arc, Egr-1 and NR2B in the AC. Black arrows indicate neurons and white arrows indicate glia. B) The number of Arc, Egr-1 and NR2B positively stained cells in the AC. C) Bars show percentage difference in OD compared to the control group (100%). Values are given as mean ± SD, n=6.\*P\<0.05 *vs* the control group. Scale bars: 30 μm.](ejh-2014-1-2294-g005){#fig005}
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